Obtaining a visa to enter the United Arab Emirates is now easier at Abu Dhabi's facilities
An increased number of applicants may be serviced each day thanks to a new AI-powered X-ray technology that will automate the reporting of tuberculosis (TB) screens, decrease radiologists' workload by up to 80%, and improve operational efficiency throughout the visa application process.
Abu Dhabi announces facilities for obtaining an entry visa to UAE
M42, a multinational tech-enabled health firm with its headquarters in Abu Dhabi, created AIRIS-TB, an AI-powered chest X-ray for tuberculosis screening facilities. Capital Health Screening Center (CHSC), M42's premier visa screening facility, has tested AIRIS-TB in more than a million scans over the course of two years according to M42's Abu Dhabi Health Data Services. The program can cut radiologist effort by up to 80% while missing zero instances of tuberculosis, according to the results of a pilot research.
The automation will allow Capital Health Screening Center to service a "unprecedented large number" of visa applications, according to CEO Ali Alsaffar.
The radiology crew at our screening center carefully evaluates hundreds of images every day; it's a labor-intensive and physically taxing process. During Abu Dhabi Global Healthcare Week, Alsaffar stated, "AI presents a revolutionary change as it operates without such constraints, whereas manual screening is limited by the number of scans a radiologist can review."
"AI can typically eliminate wait times by offering quick and effective screening services, allowing us to process an unprecedentedly high volume of visa applications and dramatically shorten turnaround times," said Alsaffar.
The device employs cutting-edge AI to identify anomalies in X-rays and promptly highlights anomalous findings for a radiologist's additional examination. It increases the scope of visa screening beyond tuberculosis and simplifies processes. Radiologists can improve patient outcomes and the experience of obtaining a visa for residents by using the time saved to identify other problems and recommend patients for follow-up care.
"AIRIS-TB is about transforming healthcare delivery and experience—it's not simply about technological advancements. Ashish Koshy, group chief operating officer, M42, stated, "It is a powerful testament to the synergy of our group's assets, which aim to solve pressing health challenges with technological innovation, setting new global standards in TB screening."
Increasing the size of operations
The technology will be made available on Malaffi, Abu Dhabi's Health Information Exchange run by M42's Abu Dhabi Health Data Services, where it may be used by more screening providers in the future for their own operations.
"Deployed at M42's flagship visa screening facility, Capital Health Screening Centre, it represents a significant stride forward for medical technology in the UAE," said Kareem Shahin, CEO of M42's Abu Dhabi Health Data Services.
Shahin emphasized that the instrument increases diagnostic accuracy and expedites the screening procedure.
"Our priorities continue to be improving patient care and making sure medical staff have access to the best resources possible. The possible installation of AIRIS-TB in Malaffi will greatly expand the number of healthcare institutions and screening centers in Abu Dhabi that can use this technology in order to grow, become more efficient, and offer better service.
With its shown effectiveness, safety, and clinical impact, AIRIS-TB is poised to revolutionize TB screening procedures and standards worldwide.
Alsaffar stated: "We are able to provide our visa applicants better services because our doctors have more time to devote to complex chest radiography results, which is a crucial opportunistic detection skill. We are eager to implement the scalable approach at the ADNOC Occupational Medical Centre, which is operated by us.
Without altering the present TB screening methodology, M42 is trying to improve AIRIS-TB's capabilities and investigate its applicability in other diagnostic domains, such as opportunistic screening of other illnesses.